Tuesday, July 3, 2012

GlaxoSmithKline settles drug-marketing case for $3 billion - latimes.com

GlaxoSmithKline settles drug-marketing case for $3 billion - latimes.com
The British pharmaceutical giant agrees to pay a record healthcare-fraud settlement for promoting a number of drugs for uses not approved by federal regulators. California will get $46 million. As part of the agreement, California is set to receive $46 million, the largest sum of the 44 states involved in the settlement. The government said that Glaxo marketed its depression drug Paxil to patients under 18, even though the Food and Drug Administration had not approved the drug for pediatric use. It also said the company promoted Wellbutrin as a weight-loss drug and for the treatment of sexual dysfunction and substance abuse addictions, and paid doctors millions of dollars to promote these unapproved uses of the drug. Doctors are permitted to prescribe drugs for "off label" conditions, but pharmaceutical companies are not allowed to market products for non-FDA-approved uses. Glaxo was also accused of failing to include important safety data to the FDA about its diabetes drug Avandia.

No comments:

Post a Comment